| Verifiedrevid | 451558531 |
|---|---|
| Iupac name | N-[2-(3-Formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide |
| Width | 220 |
| Legal us | unscheduled |
| Legal us comment | Not FDA approved |
| Cas number | 119610-26-3 |
| Atc prefix | none |
| Pubchem | 178134 |
| Chemspiderid | 155069 |
| Chembl | 2104637 |
| Unii | U0RKZ75D0T |
| C | 11 |
| H | 16 |
| N | 2 |
| O | 2 |
| Smiles | CC1=CC(=C(N1CCNC(=O)C)C)C=O |
| Stdinchi | 1S/C11H16N2O2/c1-8-6-11(7-14)9(2)13(8)5-4-12-10(3)15/h6-7H,4-5H2,1-3H3,(H,12,15) |
| Stdinchikey | ZUQSGZULKDDMEW-UHFFFAOYSA-N |
Aloracetam (INN) is a drug described as a nootropic which is closely related to, but technically not of (as it lacks a pyrrolidone ring), the racetam family of compounds.[1][2][3] It was studied by Aventis for the treatment of Alzheimer's disease,[4] but was never marketed.
See also
References
- ^ "The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances". World Health Organization. 2011. Retrieved 22 May 2015.
- ^ George CF (7 July 1998). Drug Therapy in Old Age. Wiley. ISBN 978-0-471-94149-1.
- ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 615–. ISBN 978-0-412-46630-4.
- ^ Fischer F, Matthisson M, Herrling P (2004). "List of drugs in development for neurodegenerative diseases". Neuro-Degenerative Diseases. 1 (1): 50–70. doi:10.1159/000077879. PMID 16908974